期刊文献+

毒黄素对HepG2细胞的毒性作用及其机制研究 被引量:3

The toxic effect and the mechanism of toxoflavin on HepG2 cells
原文传递
导出
摘要 目的研究不同剂量毒黄素(TXF)对HepG2细胞的毒性作用及机制。方法取3种剂量(6、12和24μg/ml)的TXF作用于HepG2细胞,以正常HepG2细胞作对照,培养24h后,台盼蓝拒染法和MTT法测定细胞生长抑制作用,倒置相差显微镜下观察HepG2细胞形态结构,透射电镜观察HepG2细胞超微结构变化,RT-PCR对Fas/FasL的表达作半定量检测。结果盼蓝拒染法检测,不同剂量的TXF对HepG2细胞均有抑制作用(P<0.01);MTT检测,不同剂量的TXF均可抑制HepG2细胞生长,并呈剂量依赖关系(P<0.01);倒置相差显微镜观察,可见细胞质空泡化;TEM观察细胞出现染色质边集现象,核仁内出现空泡等细胞凋亡现象;RT-PCR检测Fas/FasL的mRNA相对表达量,均呈现明显增高(P<0.01)。结论不同剂量TXF对HepG2细胞均有抑制作用,12μg/mlTXF对HepG2细胞毒性作用主要表现为诱导细胞凋亡。TXF可通过Fas/FasL途径导致细胞凋亡。 Objective To study the toxic effects and mechanism of different concentrations Toxoflavin(TXF) on HepG2 cells, and to provide the theory basis for the toxic effect of TXF on human being. Methods Using 1 % FBS as the con trol, TXF of 6, 12 and 24 μg/ml were co-incubated with HepG2 cells for 24 hours in vitro. Then the effect of growth inhibitors were surveyed by methods of Trypan blue dyeing and MTT. The morphosis of HepG2 was observed by inverted phase contrast microscope. The ultrastructural organization of HepG2 cells were observed by TEM. Lastly, the expression of Fas/FasL mRNA was detected by RT PCR. Results The growth of HepG2 cells was obviously inhibited. TXF inhibited the proliferation of HepG2 cells in a dose-dependent-manner (P〈0.01). Cytoplasm vacuolization could be observed by inverted phase contrast microscope. By TEM we could observe the vacuole emerged in nucleolus and chromatin rnargination. On the whole, the morphosis of HepG2 cells apoptosis was observed and TXF could induced the expression of Fas/Fast. mRNA(P〈0.01). Conclusion TXF can inhibit the growth of HepG2 cells and TXF can also induce cell apoptosis by Fas/FasL. way.
出处 《中国病原生物学杂志》 CSCD 2009年第7期493-495,共3页 Journal of Pathogen Biology
关键词 毒黄素 HEPG2细胞 凋亡 RT-PCR FAS/FASL Toxoflavin HepG2 cell apoptosis Fas/FasL
  • 相关文献

参考文献6

二级参考文献16

  • 1岳启安,赵乃昕.酵米面假单胞菌的毒黄素诱变试验研究[J].中华预防医学杂志,1989,23(2):77-79. 被引量:5
  • 2[1]Jain R,Kumar B.Immediate and delayed complications of dexamet hasone cyclophosphamide pulse (DCP) therapy[J].Dermatol,2003,30(10):713-718
  • 3[2]Zhang X,Clark AF,Yorio T.Regulation of glucocorticoid responsiveness in glaucomatous trabecular meshwork cells by glucocorticoid receptor-beta[J].Invest Ophthalmol Vis Sci,2005,46(12):4 607-4 616
  • 4[3]Lam SC,Leung YF,Chua KF.Truncation in the TIGR in individuals with and without primary open-angle glaucoma[J].Invest Ophthalmol Vis Sci,2000,41(6):1 386-1 391
  • 5岳启安,中华预防医学杂志,1989年,23卷,77页
  • 6赵乃昕,中国公共卫生,1987年,2期,65页
  • 7团体著者,中国医学科学院学报,1980年,2卷,2期,77页
  • 8团体著者,黑龙江医药,1978年,4期,15页
  • 9赵乃昕.酵米面中毒病原菌中毒及其防描[J].滩坊医学院学报,1992,14(1):69-69.
  • 10酵米面中毒病因研究协作组.酵米面中毒病因的研究[J].中国医学科学院学报,1980,2(2):77-77.

共引文献35

同被引文献47

  • 1叶富强,陈蔚文.四君子汤对胃肠道作用的药理研究[J].时珍国医国药,2005,16(1):73-74. 被引量:97
  • 2王汝俊,傅定中,邵庭荫,王建华.补中益气汤对“脾虚”大鼠胃粘膜易损伤性的复健作用研究[J].广州中医学院学报,1995,12(3):31-32. 被引量:23
  • 3丁亚男,许越.非损伤微测技术及其在生物医学研究中的应用[J].物理,2007,36(7):548-558. 被引量:18
  • 4Heist RS, Sequist LV, Engelman JA. Genetic changes in squamous cell lung cancer: a review. J Thorac Oncol, 2012, 7(5):924-933.
  • 5Ozgfil MA, Kirkil G, Seyhan EC, et al. The maximum standardized FDG uptake on PET-CT in patients with non-small cell lung cancer. Multidiscip Respir Med, 2013, 8(1):69.
  • 6Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol, 2013, 8(7):823-859.
  • 7Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res, 2012, 18(4): 1167-1176.
  • 8Choi G, Lee J, Ji JY, et al. Discovery of a potent small molecule SIRT1/2 inhibitor with anticancer effects. Int J Oncol, 2013, 43(4): 1205-121l.
  • 9Boolell V, Alamgeer M, Watkins DN, et al. The evolution of therapies in non-small cell lung cancer. Cancers (Basel), 2015, 7(3): 1815-1846.
  • 10Chen IC, Chiang WF, Huang HH, et al. Role of SIRTI in regulation of epithelial-to-mesenchymal transition in oral squamous cell carcinoma metastasis. Mol Cancer, 2014, 13:254.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部